AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026
By Marin Xavier, MD
How to sequence relapsed diffuse large B-cell lymphoma therapy in 2026: CAR-T eligibility, bispecific antibody combinations like SUNMO and STARGLO, bridging strategies, and frontline changes ahead.
CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026
By Marin Xavier, MD
How to sequence relapsed diffuse large B-cell lymphoma therapy in 2026: CAR-T eligibility, bispecific antibody combinations like SUNMO and STARGLO, bridging strategies, and frontline changes ahead.
CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026
By Marin Xavier, MD
How to sequence relapsed diffuse large B-cell lymphoma therapy in 2026: CAR-T eligibility, bispecific antibody combinations like SUNMO and STARGLO, bridging strategies, and frontline changes ahead.
Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations
By Autumn Jeong, MD
CAR-T cell therapy is the established standard second-line treatment for primary refractory or early relapsed diffuse large B-cell lymphoma, supported by mature, practice-defining trial data.
Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations
By Autumn Jeong, MD
CAR-T cell therapy is the established standard second-line treatment for primary refractory or early relapsed diffuse large B-cell lymphoma, supported by mature, practice-defining trial data.
Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations
By Autumn Jeong, MD
CAR-T cell therapy is the established standard second-line treatment for primary refractory or early relapsed diffuse large B-cell lymphoma, supported by mature, practice-defining trial data.
Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived
By Millie Das, MD
SCLC in 2026: consolidation durvalumab is standard in limited-stage disease, tarlatamab has full FDA approval, lurbinectedin maintenance is available, and antibody-drug conjugates are advancing in late-stage trials.
Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived
By Millie Das, MD
SCLC in 2026: consolidation durvalumab is standard in limited-stage disease, tarlatamab has full FDA approval, lurbinectedin maintenance is available, and antibody-drug conjugates are advancing in late-stage trials.
Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived
By Millie Das, MD
SCLC in 2026: consolidation durvalumab is standard in limited-stage disease, tarlatamab has full FDA approval, lurbinectedin maintenance is available, and antibody-drug conjugates are advancing in late-stage trials.
When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
By Loan Retchless, ARNP
Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage
When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
By Loan Retchless, ARNP
Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage
When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
By Loan Retchless, ARNP
Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage
Upper GI Cancer Updates: Perioperative Immunotherapy and New HER2-Directed Options
By Kayla Weiss Miranda, MD
Perioperative immunotherapy is the new standard for resectable gastric and GEJ cancer, and zanidatamab offers a new HER2-directed option for metastatic disease, based on MATTERHORN, NeoSUMMIT-01, and HERIZON-GEA-01.
Upper GI Cancer Updates: Perioperative Immunotherapy and New HER2-Directed Options
By Kayla Weiss Miranda, MD
Perioperative immunotherapy is the new standard for resectable gastric and GEJ cancer, and zanidatamab offers a new HER2-directed option for metastatic disease, based on MATTERHORN, NeoSUMMIT-01, and HERIZON-GEA-01.
Upper GI Cancer Updates: Perioperative Immunotherapy and New HER2-Directed Options
By Kayla Weiss Miranda, MD
Perioperative immunotherapy is the new standard for resectable gastric and GEJ cancer, and zanidatamab offers a new HER2-directed option for metastatic disease, based on MATTERHORN, NeoSUMMIT-01, and HERIZON-GEA-01.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
By Krishna Rekha Moturi, MBBS
Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.
The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
By Krishna Rekha Moturi, MBBS
Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.
The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
By Krishna Rekha Moturi, MBBS
Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.